ADC Therapeutics SA (ADCT)
4.09
-0.04
(-0.97%)
USD |
NYSE |
May 16, 16:00
4.08
-0.01
(-0.24%)
After-Hours: 20:00
ADC Therapeutics Revenue (Quarterly): 18.05M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 18.05M |
| December 31, 2023 | 16.79M |
| September 30, 2023 | 14.49M |
| June 30, 2023 | 19.28M |
| March 31, 2023 | 18.99M |
| December 31, 2022 | 69.80M |
| September 30, 2022 | 76.32M |
| June 30, 2022 | 17.29M |
| March 31, 2022 | 46.50M |
| December 31, 2021 | 17.01M |
| Date | Value |
|---|---|
| September 30, 2021 | 13.15M |
| June 30, 2021 | 3.76M |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 1.962M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.962M
Minimum
Jun 2019
76.32M
Maximum
Sep 2022
25.65M
Average
17.29M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Novartis AG | 12.12B |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -- |
| Addex Therapeutics Ltd | 0.1731M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -46.61M |
| Total Expenses (Quarterly) | 51.42M |
| EPS Diluted (Quarterly) | -0.56 |
| Enterprise Value | 272.51M |
| Gross Profit Margin (Quarterly) | 86.10% |
| Profit Margin (Quarterly) | -258.2% |
| Earnings Yield | -67.73% |
| Normalized Earnings Yield | -67.18 |